These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 34133089

  • 1. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK.
    J Clin Psychiatry; 2021 Jun 15; 82(4):. PubMed ID: 34133089
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I.
    Psychiatry Clin Neurosci; 2020 Feb 15; 74(2):140-148. PubMed ID: 31725942
    [Abstract] [Full Text] [Related]

  • 3. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A.
    J Psychiatry Neurosci; 2015 May 15; 40(3):174-86. PubMed ID: 25350320
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 15; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 5. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E.
    Eur Neuropsychopharmacol; 2016 Jun 15; 26(6):979-93. PubMed ID: 27139079
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J, Wang Z, Li E.
    Afr Health Sci; 2019 Mar 15; 19(1):1716-1726. PubMed ID: 31149002
    [Abstract] [Full Text] [Related]

  • 7. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms.
    Xue L, Bocharova M, Young AH, Aarsland D.
    J Affect Disord; 2024 Sep 15; 361():74-81. PubMed ID: 38838790
    [Abstract] [Full Text] [Related]

  • 8. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC, Loft H, McIntyre RS.
    J Affect Disord; 2018 Feb 15; 227():787-794. PubMed ID: 29689693
    [Abstract] [Full Text] [Related]

  • 9. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA, Loft H, Olsen CK.
    J Affect Disord; 2019 May 01; 250():35-42. PubMed ID: 30826492
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W.
    CNS Spectr; 2017 Aug 01; 22(4):348-362. PubMed ID: 27869048
    [Abstract] [Full Text] [Related]

  • 11. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul 01; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 12. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
    McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK.
    Int J Neuropsychopharmacol; 2016 Jun 15; 19(10):. PubMed ID: 27312740
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
    McIntyre RS, Lophaven S, Olsen CK.
    Int J Neuropsychopharmacol; 2014 Oct 15; 17(10):1557-67. PubMed ID: 24787143
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC.
    J Clin Psychiatry; 2017 Jan 15; 78(1):115-121. PubMed ID: 27780334
    [Abstract] [Full Text] [Related]

  • 15. Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder.
    McIntyre RS, Necking O, Schmidt SN, Reines E.
    J Affect Disord; 2024 Oct 15; 363():430-435. PubMed ID: 39032712
    [Abstract] [Full Text] [Related]

  • 16. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A, Barker A.
    BMC Psychiatry; 2014 Sep 27; 14():276. PubMed ID: 25260373
    [Abstract] [Full Text] [Related]

  • 17. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huang IC, Chang TS, Chen C, Sung JY.
    Int J Neuropsychopharmacol; 2022 Dec 12; 25(12):969-978. PubMed ID: 35981958
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.
    Int Clin Psychopharmacol; 2012 Jan 12; 27(1):27-39. PubMed ID: 22027845
    [Abstract] [Full Text] [Related]

  • 19. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M, Christensen MC, Florea I, Loft H, Fagiolini A.
    J Affect Disord; 2023 May 01; 328():345-354. PubMed ID: 36708956
    [Abstract] [Full Text] [Related]

  • 20. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov 01; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.